Mayne Pharma Group Limited (MAYNF) Income Statement Analysis

See more : Beneficient (BENFW) Income Statement Analysis – Financial Results

Complete financial analysis of Mayne Pharma Group Limited (MAYNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mayne Pharma Group Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Credit Suisse High Yield Bond Fund, Inc. (DHY) Income Statement Analysis – Financial Results
Arçelik Anonim Sirketi (ARCLK.IS) Income Statement Analysis – Financial Results
Nan Nan Resources Enterprise Limited (1229.HK) Income Statement Analysis – Financial Results
Investeringsforeningen Bankinvest Globale – Aktier A Fund (BAIGLA.CO) Income Statement Analysis – Financial Results
Chrysalis Investments Limited (CHRY.L) Income Statement Analysis – Financial Results

Mayne Pharma Group Limited (MAYNF)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.maynepharma.com

About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	388.15M	183.59M	423.92M	400.32M	456.60M	523.96M	529.14M	571.74M	266.19M	140.32M	142.18M	82.26M	51.08M	48.77M	37.04M	1.04M	820.81K	140.11K
Cost of Revenue	169.62M	156.75M	253.77M	205.58M	231.49M	222.60M	266.26M	256.83M	98.91M	61.43M	68.20M	44.44M	29.34M	26.86M	19.13M	0.00	0.00	0.00
Gross Profit	218.53M	26.84M	170.15M	194.74M	225.11M	301.36M	262.88M	314.90M	167.28M	78.89M	73.98M	37.82M	21.74M	21.91M	17.92M	1.04M	820.81K	140.11K
Gross Profit Ratio	56.30%	14.62%	40.14%	48.65%	49.30%	57.52%	49.68%	55.08%	62.84%	56.22%	52.03%	45.98%	42.55%	44.92%	48.37%	100.00%	100.00%	100.00%
Research & Development	21.56M	15.73M	14.66M	18.91M	24.75M	25.81M	12.30M	8.28M	8.73M	5.59M	4.55M	3.99M	4.02M	5.97M	5.29M	3.15M	2.24M	822.88K
General & Administrative	55.53M	58.05M	-28.65M	29.52M	61.83M	81.95M	75.95M	78.95M	49.77M	28.87M	25.58M	15.08M	7.26M	6.77M	4.49M	2.02M	2.05M	1.14M
Selling & Marketing	130.70M	125.95M	104.60M	56.82M	74.20M	76.67M	60.97M	39.12M	38.03M	16.26M	9.20M	4.42M	1.28M	1.32M	387.61K	0.00	87.08K	0.00
SG&A	243.08M	197.55M	75.95M	86.34M	136.03M	158.62M	136.93M	118.07M	87.80M	45.13M	34.78M	19.50M	8.53M	8.09M	4.88M	2.02M	2.05M	1.14M
Other Expenses	0.00	12.63M	-7.17M	-14.24M	15.44M	-7.94M	4.67M	27.50M	-1.29M	3.98M	3.57M	-8.37M	4.33M	2.13M	-345.35K	609.88K	-61.62K	0.00
Operating Expenses	264.63M	213.28M	171.69M	173.44M	245.34M	278.92M	229.11M	201.53M	119.16M	70.02M	50.35M	31.89M	17.26M	21.61M	15.49M	5.16M	4.29M	1.96M
Cost & Expenses	434.26M	370.03M	425.46M	379.02M	476.83M	501.52M	495.37M	458.37M	218.08M	131.46M	118.55M	76.33M	46.60M	48.47M	34.61M	5.16M	4.29M	1.96M
Interest Income	6.57M	6.72M	461.00K	687.00K	788.00K	1.02M	112.00K	286.00K	461.00K	355.00K	251.00K	394.00K	181.00K	264.00K	206.15K	430.01K	820.81K	140.11K
Interest Expense	34.50M	10.45M	32.10M	32.35M	31.54M	17.44M	17.25M	11.48M	2.44M	5.95M	4.35M	2.31M	28.00K	1.81M	1.48M	0.00	0.00	0.00
Depreciation & Amortization	68.46M	65.44M	55.18M	68.19M	84.56M	94.50M	79.88M	73.67M	21.38M	13.50M	9.86M	7.37M	3.84M	6.10M	5.32M	26.49K	22.33K	4.97K
EBITDA	-87.13M	-121.00M	-46.34M	75.47M	88.06M	109.94M	120.55M	201.08M	73.65M	30.69M	42.23M	8.93M	13.37M	8.06M	7.40M	-4.13M	-3.47M	-1.82M
EBITDA Ratio	-22.45%	-65.91%	21.80%	18.85%	19.29%	20.98%	22.78%	38.71%	27.67%	21.87%	29.70%	10.94%	24.76%	17.48%	19.98%	-396.68%	-423.09%	-1,301.80%
Operating Income	-45.86M	-186.44M	11.32M	7.28M	3.50M	15.44M	40.67M	147.63M	52.28M	17.19M	32.37M	1.63M	8.81M	2.43M	2.08M	-4.15M	-3.50M	-1.83M
Operating Income Ratio	-11.81%	-101.56%	2.67%	1.82%	0.77%	2.95%	7.69%	25.82%	19.64%	12.25%	22.77%	1.98%	17.25%	4.98%	5.63%	-399.23%	-425.81%	-1,305.35%
Total Other Income/Expenses	-144.23M	-83.25M	-134.68M	-271.17M	-97.48M	-376.16M	-200.56M	-31.69M	-2.44M	-5.95M	-7.51M	-6.68M	-1.06M	-3.93M	-209.06K	26.49K	22.33K	4.97K
Income Before Tax	-190.09M	-269.70M	-217.82M	-263.89M	-135.37M	-353.72M	-166.79M	115.94M	49.84M	11.24M	28.02M	-703.00K	7.75M	-1.50M	604.83K	-4.13M	-3.47M	-1.82M
Income Before Tax Ratio	-48.97%	-146.91%	-51.38%	-65.92%	-29.65%	-67.51%	-31.52%	20.28%	18.72%	8.01%	19.71%	-0.85%	15.17%	-3.08%	1.63%	-396.68%	-423.09%	-1,301.80%
Income Tax Expense	-21.47M	47.75M	56.13M	-54.81M	-40.83M	-69.97M	-32.53M	29.91M	15.31M	3.71M	6.73M	2.14M	1.60M	-3.18M	-2.65M	-363.70K	-83.95K	0.00
Net Income	-174.23M	-316.42M	-263.34M	-208.42M	-92.79M	-280.87M	-133.98M	88.57M	37.36M	7.76M	21.29M	-2.84M	6.15M	1.68M	3.25M	-3.76M	-3.47M	-1.82M
Net Income Ratio	-44.89%	-172.35%	-62.12%	-52.06%	-20.32%	-53.60%	-25.32%	15.49%	14.03%	5.53%	14.97%	-3.46%	12.05%	3.44%	8.78%	-361.71%	-423.09%	-1,301.80%
EPS	-2.12	-3.85	-3.20	-2.65	-1.21	-3.81	-1.83	1.24	0.95	0.22	0.69	-0.13	0.58	0.16	0.38	-0.71	-0.65	-0.59
EPS Diluted	-2.19	-3.67	-3.20	-2.65	-1.21	-3.81	-1.83	1.21	0.92	0.22	0.66	-0.13	0.58	0.16	0.37	-0.71	-0.65	-0.59
Weighted Avg Shares Out	82.19M	82.18M	82.30M	78.58M	76.47M	73.75M	73.14M	71.68M	39.12M	34.50M	31.02M	22.02M	10.60M	10.49M	8.59M	5.31M	5.31M	3.08M
Weighted Avg Shares Out (Dil)	79.62M	86.26M	82.30M	78.58M	76.47M	73.75M	73.14M	73.08M	40.43M	35.53M	32.07M	22.02M	10.67M	10.64M	8.90M	5.31M	5.31M	3.08M

FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH

November 4, 2024prnewswire.com

Proposed Ruling Aims to Eliminate Out-of-Pocket Costs for Contraception, Enhancing Access for Women in the United States ADELAIDE, Australia and RALEIGH, N.C. , Nov. 4, 2024 /PRNewswire/ -- Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), welcomes the...